5 Easy Ways to Avoid Antibody Production Mistakes

Antibody or immunoglobulin is a protective protein which is produced by the immune system in response to a foreign body or antigen. These antibodies recognise the antigen and neutralise it by phagocytosis. A wide range of substances can act as antigens including the disease-causing pathogen and other toxic materials like insect venom. Currently, medicine has evolved into a new era of personalised therapy. It has led to Monoclonal Antibody Development (mAb) which can treat a wide range of diseases.

               

 Monoclonal antibodies develop from identical immune cells which are all clones of a unique parent cell. They show monovalent affinity in recognising the antigen. Since the first licensing of the monoclonal antibodies 34 years ago, its market has seen exponential development in the last few years. Now they used to treat a wide range of diseases like cancer, arthritis, multiple sclerosis and heart diseases to name a few. Since monoclonal antibody is essential in Medical Science, the Pharmaceutical companies exercise extra cares in their development process. Here are 5 easy ways to avoid antibody production mistakes.

1.    Proper Storage of Sample

The first thing which Pharmaceutical Companies consider in the monoclonal antibody development is the appropriate storage of sample with a correct range of temperature and zero contamination. Any lapse in the storing of samples and shipment between facilities can lead to stress among the sample cells. It would further hamper the antibody production, and it requires enormous effort to bring the sample cells back to the optimal production level. So, companies exercise strict temperature control in storing the samples and its shipment from facility-to-facility.

Another problem which Pharmaceutical Companies face is the contamination with mycoplasma. Cell culture begins to deteriorate due to this contamination. It alters the behaviour and metabolism of the sample cells. So, proper segregation of cells and use of sterilised equipment helps to reduce contamination of the sample.

2.    Maintaining Complete Record and Documentation

In many cases the Pharmaceutical Company undergo mergers and buyouts, the clones in this process are sold or passed on without proper documentation. We know that a viable antibody cell line has immense promise and commercial potential. However, lack of documentation can put to waste months of hard work of the Scientists spent in segregating the clones.

3.    Patience while Developing the Cell Lines

Scientists should exercise patience while developing antibody cell lines and allow the necessary time for the culture to grow. If the cells are developed quickly or chosen improperly, then the yield of antibodies would be compromised. Production cost would also rise in the treatment of cells to again perform optimally. So, the Scientist should keep in mind that the antibodies may be used for future commercialisation and plan a long-term strategy for the sample cell lines.

4.    Assess the Partner

The Companies should access the history, capacity and flexibility of the partner for antibody production before selecting them. The partnership should only progress with those companies having proper quality control assurance, Standard Operating Procedure (SOP) and proven track record.

5.    Strong Communication among Partners

Once a Company has selected a partner for monoclonal antibody development, it is important to share all the information regarding the segregation and preparation of the clones. You should let your partner know the ultimate goal of the antibodies. Timely, proactive communication among the partners can go a long way in developing viable antibodies.

So, this was, in brief, 5 easy ways to avoid antibody production mistakes. Whenever we talk of monoclonal antibody development, the name of Kemwell Biopharma comes at the top of the list. This Pharmaceutical Company is a leading producer of drugs for pioneering brands like Bayer, GlaxoSmithKline, Merck KGaA, and Novartis. The established names in the field of Medicine have faith in the monoclonal antibodies Kemwell Biopharma develops.

For More Information Visit Us: http://www.kemwellbiopharma.com